Bausch + Lomb stock gains 1 percent as Q2 sales rise 9.1 percent

Published on 10/04/2026 at 11:54 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bausch + Lomb stock was last at USD 17.11 on October 2, 2026, up 1.00 percent. Q2 revenue reached USD 1.394 billion, up 9.1 percent year over year.

BLCO, CA0717051076, Illustration mit AI erstellt.

Bausch + Lomb stock (ISIN CA0717051076) was last at USD 17.11 on the NYSE on October 2, 2026, up 1.00 percent from the prior close. The company listed a review article on patient-centric dry-eye management on October 1, according to Bausch + Lomb, keeping product execution at the center of the current investor discussion.

Revenue grows while EPS misses

Bausch + Lomb generated USD 1.394 billion of revenue in Q2 2026, a 9.1 percent increase from the year-earlier quarter. The surgical business was the fastest-growing segment at 16 percent, while premium intraocular lenses increased 175 percent and grew from 6 percent to 13 percent of surgical revenue, according to DK Street Journal.

The earnings mix was less decisive than sales growth. MarketBeat reported Q2 adjusted earnings per share of USD 0.15 against a USD 0.16 consensus estimate, while revenue exceeded the USD 1.37 billion estimate, according to MarketBeat. For investors, the contrast puts margin conversion and earnings delivery alongside headline sales growth.

Analyst targets leave 11.9 percent upside

The analyst picture is constructive but not unanimous. MarketBeat listed a Hold consensus from 15 brokerages, comprising eight Hold ratings, six Buys and one Sell, with an average 12-month price target of USD 19.1538; the published target range was USD 17.00 to USD 24.00.

Against the October 2 reference price of USD 17.11, the average target lies 11.9 percent above the price. Leerink Partners initiated coverage with an Outperform rating and a USD 24.00 target on September 9, a view that sits at the top of the published range.

October 28 sets the next checkpoint

ToAlpha lists October 28, 2026 as the next earnings date for BLCO, giving investors a dated checkpoint for the next test of surgical growth and profitability, according to ToAlpha. The stock's USD 13.77 to USD 18.92 52-week range places the October 2 price 9.6 percent below its yearly high.